{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:54:33Z","timestamp":1782849273535,"version":"3.54.5"},"reference-count":61,"publisher":"SAGE Publications","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"funder":[{"DOI":"10.13039\/501100001826","name":"ZonMw","doi-asserted-by":"publisher","award":["446002902"],"award-info":[{"award-number":["446002902"]}],"id":[{"id":"10.13039\/501100001826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100021821","name":"Oncode Institute","doi-asserted-by":"publisher","award":["P2019-0017"],"award-info":[{"award-number":["P2019-0017"]}],"id":[{"id":"10.13039\/501100021821","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["Ther Adv Med Oncol"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:sec>\n                    <jats:title>Background:<\/jats:title>\n                    <jats:p>The role of stroma in esophagogastric cancer is ambiguous, with both tumor-promoting and tumor-restrictive properties. Several non-invasive biomarkers of stroma have recently been identified, but their relationship with stromal composition and clinical outcome in esophagogastric cancer remains insufficiently understood.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives:<\/jats:title>\n                    <jats:p>We aimed to investigate the association of serum stromal biomarkers with overall survival and stroma composition in esophagogastric cancers.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Design:<\/jats:title>\n                    <jats:p>Eleven stromal biomarkers were retrospectively measured in pre-treatment serum of 78 patients with esophagogastric cancer and 11 healthy controls.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods:<\/jats:title>\n                    <jats:p>Elastic net Cox regression was applied to associate serum concentration of stromal biomarkers with overall survival in patients with esophagogastric cancer. These associations were later confirmed with Kaplan\u2013Meier curves and multivariate Cox regression analysis. RNA-sequencing was performed on 17 matched tumor biopsies and an independent validation cohort of 100 pre-treatment biopsies to explore the relation between stromal biomarker and stromal subtype.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results:<\/jats:title>\n                    <jats:p>This study revealed that serum formation fragment of collagen V as a stromal biomarker was high in patients with esophagogastric cancer compared to healthy subjects. A high serum concentration of the formation fragment of collagen V was independently prognostically favorable in patients with esophagogastric cancer. The formation of collagen V correlated with a distinct normal stroma subtype in the matched tumor biopsies. A gene signature specific for the formation fragment of collagen V was also independently prognostically favorable and correlated with a normal stroma subtype in the validation cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>In conclusion, the formation of collagen V reflects a distinct normal stroma subtype in patients with esophagogastric cancer that associates with favorable outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/17588359261459109","type":"journal-article","created":{"date-parts":[[2026,6,28]],"date-time":"2026-06-28T12:37:12Z","timestamp":1782650232000},"update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":0,"title":["Serum levels of the C-terminal pro-peptide of type V collagen have prognostic potential and are associated with a normal subtype of desmoplasia in a retrospective cohort of patients with esophagogastric cancer"],"prefix":"10.1177","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8162-0804","authenticated-orcid":false,"given":"Benthe H.","family":"Doeve","sequence":"first","affiliation":[{"name":"Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands"},{"name":"Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, the Netherlands"},{"name":"Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neel I.","family":"Nissen","sequence":"additional","affiliation":[{"name":"Biomarkers &amp; Research, Nordic Bioscience, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vera","family":"Weeda","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands"},{"name":"Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, the Netherlands"},{"name":"Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark P. G.","family":"Dings","sequence":"additional","affiliation":[{"name":"Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, the Netherlands"},{"name":"Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sybren L.","family":"Meijer","sequence":"additional","affiliation":[{"name":"Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, the Netherlands"},{"name":"Department of Pathology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1274-5643","authenticated-orcid":false,"given":"Hanneke W. M.","family":"van Laarhoven","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands"},{"name":"Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maarten F.","family":"Bijlsma","sequence":"additional","affiliation":[{"name":"Laboratory of Experimental Oncology and Radiobiology, Amsterdam UMC, University of Amsterdam, RDC Adore ZH 3J079, Van der Boechorststraat 6b, Amsterdam 1081BT, The Netherlands"},{"name":"Imaging and Biomarkers, Cancer Center Amsterdam, Amsterdam, the Netherlands"},{"name":"Laboratory for Experimental Oncology and Radiobiology, Center for Experimental and Molecular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands"},{"name":"Oncode Institute, Amsterdam, the Netherlands"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicholas","family":"Willumsen","sequence":"additional","affiliation":[{"name":"Biomarkers &amp; Research, Nordic Bioscience, Herlev, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"179","published-online":{"date-parts":[[2026,6,28]]},"reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21660"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature20805"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.07.003"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdw350"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2111380"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)00797-2"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2032125"},{"issue":"18","key":"e_1_3_4_9_2","article-title":"Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line HER2-positive advanced gastric cancer","volume":"27","author":"Van Cutsem E","year":"2009","unstructured":"Van Cutsem E, et al. Efficacy results from the ToGA trial: a phase III study of trastuzumab added to standard chemotherapy in first-line HER2-positive advanced gastric cancer. J Clin Oncol 2009; 27(18): LBA4509.","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_10_2","article-title":"Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): first results of the CheckMate 648 study","author":"Chau I","unstructured":"Chau I, et al. Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): first results of the CheckMate 648 study. J Clin Oncol 2021; 39(15_suppl): LBA4001.","journal-title":"J Clin Oncol"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)01234-4"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10555-014-9541-1"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/PPO.0000000000000127"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13046-019-1110-6"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1820459116"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32364"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.32099"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejpb.2021.05.007"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33947"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.6740"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.3892\/or.2020.7606"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1186\/1479-5876-8-99"},{"key":"e_1_3_4_23_2","first-page":"39","article-title":"The value of tumor-stroma ratio as predictor of pathologic response after neoadjuvant chemoradiotherapy in esophageal cancer","volume":"20","author":"van Pelt GW","year":"2020","unstructured":"van Pelt GW, et al. The value of tumor-stroma ratio as predictor of pathologic response after neoadjuvant chemoradiotherapy in esophageal cancer. Clin Transl Radiat Oncol 2020; 20: 39\u201344.","journal-title":"Clin Transl Radiat Oncol"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-018-0202-y"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/JTO.0b013e318260dfe8"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cub.2020.06.081"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1172\/JCI136760"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-75541-4"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1038\/ng.3398"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.3233\/CBM-150520"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.303"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-13-554"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.32751"},{"key":"e_1_3_4_34_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2230.2003.01326.x"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmolb.2023.1158058"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.34356"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-018-0474-z"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12967-021-02701-z"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-79608-0"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-56268-3"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.33551"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2010.03.012"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinbiochem.2012.02.007"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tranon.2019.02.004"},{"issue":"3","key":"e_1_3_4_45_2","first-page":"303","article-title":"The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters","volume":"5","author":"Nielsen MJ","year":"2013","unstructured":"Nielsen MJ, et al. The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am J Transl Res 2013; 5(3): 303.","journal-title":"Am J Transl Res"},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.3109\/1354750X.2011.584131"},{"key":"e_1_3_4_47_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00432-018-2799-x"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpba.2021.114272"},{"issue":"4","key":"e_1_3_4_49_2","first-page":"403","article-title":"Circulating levels of citrullinated and MMP-degraded vimentin (VICM) in liver fibrosis related pathology","volume":"4","author":"Vassiliadis E","year":"2012","unstructured":"Vassiliadis E, et al. Circulating levels of citrullinated and MMP-degraded vimentin (VICM) in liver fibrosis related pathology. Am J Transl Res 2012; 4(4): 403.","journal-title":"Am J Transl Res"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12102786"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)61602-X"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2020.7631"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1038\/s43856-024-00512-z"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-018-0096-9"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1038\/srep30599"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00018-022-04226-0"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1002\/path.6207"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.26031"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccr.2014.04.021"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.613534"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1042\/bse0520113"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-022-01670-1"}],"container-title":["Therapeutic Advances in Medical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261459109","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/full-xml\/10.1177\/17588359261459109","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.sagepub.com\/doi\/pdf\/10.1177\/17588359261459109","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:24:07Z","timestamp":1782847447000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.sagepub.com\/doi\/10.1177\/17588359261459109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":61,"alternative-id":["10.1177\/17588359261459109"],"URL":"https:\/\/doi.org\/10.1177\/17588359261459109","relation":{},"ISSN":["1758-8359","1758-8359"],"issn-type":[{"value":"1758-8359","type":"print"},{"value":"1758-8359","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"article-number":"17588359261459109"}}